Migraine and obesity are linked, and both are common. So the question is old and the data are new. Denmark keeps national prescription registers. Somebody used them.
What was measured
Everyone who started semaglutide for weight management between December 2022 and December 2024 was included. That is 189,392 adults, 68% women, median age 50. Each person’s first dispensing set the clock. The study looked back 24 months and forward 12. [1] The outcome was triptan consumption, counted in defined daily doses per 10,000 people per month.
Note what that is. Triptans treat an attack that has already started. Dispensing them is a proxy for how often attacks happen. It is a good proxy and it is not the thing itself, a distinction endpoint choice makes constantly.
The result
Before initiation, triptan use was climbing. After it, the trend reversed. The decline was 13 defined daily doses per month per 10,000 people (95% CI −25 to −1.3). At twelve months that came to a 7% relative reduction — a rate ratio of RR = 0.93, 95% CI 0.88 to 0.97.
Where it came from matters more than the headline. Existing triptan users cut their consumption: RR = 0.86, 95% CI 0.82 to 0.90. The monthly rate of new triptan users barely moved. So this is people who already had migraine using less, not fewer people developing it.
The subgroups split cleanly. Women fell 8%: RR = 0.92, 95% CI 0.88 to 0.97. Men showed no statistically significant change. The largest reductions were in people aged 18 to 35, at RR = 0.86, 95% CI 0.78 to 0.94, and in people who had previously taken a migraine preventive, at RR = 0.88, 95% CI 0.82 to 0.94.
What the design cannot rule out
An interrupted time series compares a population to its own past. There is no control group. Everything else that happens when somebody starts a weight-loss drug happens inside the measurement window.
People who start these drugs lose weight. They often eat differently and sleep differently. Many are titrating upward through the same months, which changes more than the dose. Some stop other medications. Some are seeing a clinician regularly for the first time in years. Any of those could move triptan dispensing on its own. The study cannot separate them, and it does not claim to.
There is also a plainer possibility. Nausea is common early on. A person feeling sick may fill fewer prescriptions of anything. The effect here was gradual rather than abrupt, which argues against that, but it is not excluded.
Is seven per cent worth anything
On its own, no. Seven per cent of triptan consumption is not a migraine treatment. The approved preventives do far better and they are cheap. Nobody should buy this drug for headaches.
As a secondary benefit it is more interesting. If you are taking the drug anyway and you have migraine, this is a modest reason to expect less. That is the honest frame, and it is the frame most real-world findings deserve.
The money question is simpler. These drugs are priced for weight loss, and a headache benefit does not change what a month costs. You can see the range in the price check. Nothing on this roster is sold for migraine, and no seller claims it.